GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.86M | 10.55M | 8.95M | 6.56M | 6.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.34M | 13.34M | 12.42M | 10.59M | 10.81M |
| Operating Income | -16.34M | -13.34M | -12.42M | -10.59M | -10.81M |
| Income Before Tax | -33.50M | -59.15M | -57.09M | -37.83M | -38.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.50 | -59.15 | -57.09 | -37.83 | -38.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.50M | -59.15M | -57.09M | -37.83M | -38.13M |
| EBIT | -16.34M | -13.34M | -12.42M | -10.59M | -10.81M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -82.07 | -351.99 | -357.48 | -343.62 | -361.12 |
| Normalized Basic EPS | -43.36 | -211.61 | -221.96 | -220.36 | -231.88 |
| EPS Diluted | -82.07 | -351.99 | -357.48 | -343.62 | -361.12 |
| Normalized Diluted EPS | -43.36 | -211.61 | -221.96 | -220.36 | -231.88 |
| Average Basic Shares Outstanding | 3.44M | 2.00M | 881.40K | 452.60K | 384.40K |
| Average Diluted Shares Outstanding | 3.44M | 2.00M | 881.40K | 452.60K | 384.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.68% | -0.39% | -0.40% | -0.22% | -- |